As the result of intensive studies of 9ctte respiratory infection in military populations-from 1941 to 1946, an entity termed "acute respiratory disease" was described by the Commission on Acute Respiratory Diseases (1-4). This syndrome, for convenience, was termed "ARD," and this designation will be employed hereafter. ARD is an acute febrile respiratory infection of short duration with both constitutional symptoms and localized respiratory symptoms characterized predominately by cough and hoarseness (1, 2). In addition, irritated throat, nasal obstruction, and chest pain were frequent complaints. Epidemiological investigation (1) as well as human transmission experiments (3, 4) indicated that the incubation period of this infection was five to six days, and that during convalescence there developed an homologous immunity but not heterologous resistance to common cold or primary atypical pneumonia (4). It was postulated as a result of these investigations (1-4) that ARD was an entity distinguishable from other acute respiratory illnesses such as common cold, streptococcal pharyngitis and tonsillitis, and primary atypical pneumonia, and that it was caused by a single filterable agent, probably a virus, or a closely related group of agents. Attempts to isolate an agent in experimental animals and chick embryos were not successful.
atypical pneumonia (4) . It was postulated as a result of these investigations (1) (2) (3) (4) that ARD was an entity distinguishable from other acute respiratory illnesses such as common cold, streptococcal pharyngitis and tonsillitis, and primary atypical pneumonia, and that it was caused by a single filterable agent, probably a virus, or a closely related group of agents. Attempts to isolate an agent in experimental animals and chick embryos were not successful.
Although ARD ruses are frequently observed. Moreover, ARD continues to be an important respiratory infection in the Armed Forces. These considerations have stimulated continued investigation of this disease in order to delineate it further and to isolate the causative agent or agents.
The multiple isolations of cytopathogenic agents from tonsils and adenoids grown in tissue culture by Rowe, Huebner, Gilmore, Parrott, and Ward (5) indicated the existence of a new group of viruses which propagate in the upper respiratory tract of man and suggested a new approach to the investigation of acute undifferentiated respiratory infections. Independently, Hilleman and Werner (6) isolated in tissue culture 5 strains of cytopathogenic agents from cases of acute respiratory diseases which occurred during an influenzalike epidemic at Fort Leonard Wood, Missouri, during the winter of 1952-53. The majority of illnesses which occurred during this epidemic resembled ARD; some had pulmonary infiltration and were considered to be primary atypical pneumonia. Neither cold hemagglutinins nor agglutinins to streptococcus MG developed in patients with the latter type of illness. Hilleman and Werner demonstrated that the majority of patients studied had a rise in neutralizing antibodies against one of the strains isolated, the RI-67 strain (6) .
The isolation of an agent, presumably a virus, from cases of ARD (6) immediately suggested an opportunity to establish the etiology of ARD and to test directly the hypotheses proposed by the Commission on Acute Respiratory Diseases (1) (2) (3) (4) . In addition, it was of interest to determine the relationship of the agents isolated by Rowe and co-workers (5) , called "adenoid de- generation" or "A.D." agents, to the RI-67 agent.
The results of experiments carried out to study these points are the subject of this report. A preliminary summary of certain of these data has been presented elsewhere (7) .
MATERIALS AND METHODS
Viruses. 2 The viruses employed were the RI-67 strain of the "new acute respiratory disease virus" isolated by Hilleman and Werner and the prototype strains of Types I, II, and III "adenoid degeneration" agents isolated by Rowe, Huebner, Gilmore, Parrott, and Ward (5) .
Pools of seed virus were prepared by passage in strain HeLa cell cultures (8) Infectious Diseases, National Institutes of Health.
Tissue culture. The methods employed were modifications of those described by Scherer, Syverton, and Gey (8) for the propagation of the single cell line derived from an epidermoid carcinoma of the cervix of the uterus, designated strain HeLa. A HeLa cell culture was obtained from Dr. J. T. Syverton and has been maintained in serial passage for one year.
Cellular cultivation. Propagation of cells was carried out in bottles (200 ml. square screw-cap Kimble neutraglass, or 32 oz. flat-side Duraglas prescription, sealed with white rubber stoppers), or in. 16 by 150 mm. screwcap test tubes. Cells in bottles and tubes were incubated at 360 C. in a stationary position. Tubes were maintained at a 50 angle in specially constructed racks, and bottles were kept flat on the incubator shelves. For cultivation of cells a nutritive medium was employed composed of 25 per cent human serum, 2 per cent chick embryo extract (50 per cent), 5 per cent chick embryo ultrafiltrate (50 per cent),3 and 68 per cent Hanks balanced salt solution. Penicillin and streptomycin were added to make a final concentration of 50 units and 0.5 mg. per milliliter of each, respectively. For preparation and distribution of cell suspensions, silicon coated glassware was used. With a rubber policeman placed on the curved end of a glass rod, HeLa cells were scraped from the bottle wall into 2 to 6 ml. of the clarified nutritive fluid in which they had been grown. Trypsin was not employed. The cellular sheets and clumps were disrupted by drawing back and forth through a 22 gauge needle attached to a 3 ml. Cornwall spring-activated syringe for 1.5 to 3 minutes. By this method a suspension was prepared composed almost entirely of single cells with only an occasional small clump of cells present. The number of cells per milliliter of suspension was determined by direct microscopic enumeration in a hemocytometer. The concentration of cells was adjusted to 80,000 per ml. by dilution with nutrient fluid and dispensed into bottles in 10 (3, 4) . Sera from these patients had been saved and were available for this study. To determine whether the RI-67 agent isolated by Hilleman and Werner (6) was associated with-any of these acute respiratory infections, neutralization titrations were carried out with this virus and the reconstituted lyophilized sera obtained during the acute and convalescent stages of the donors' illnesses. The results of these titrations are summarized in Table I . Development of antibodies against the RI-67 agent occurred in the patients who had ARD and' bronchitis resembling atypical pneumonia, but not in those with primary atypical pneumonia or with the severe or mild forms of common cold. The (3, 4) . Neutralization titrations carried out with sera from donors of these secretions against the RI-67 agent not only tended to confirm these findings, but also suggested that this new agent was etiologically associated with ARD. To extend these preliminary findings, titrations were carried out with sera from recipients in the 1945 transmission experiments. The results of these titrations are presented in Figure  1 along with the clinical results of the inoculation of control autogenous filtrates and infected materials from patients with ARD, primary atypical pneumonia and common cold (1, 4 who received ARD secretions and not in volunteers inoculated with autogenous, common cold or primary atypical pneumonia filtrates. In those instances in which sera were available two to three weeks following inoculation of ARD secretions, it was possible to demonstrate that antibodies developed in relation to the inoculation and, in most instances, concurrent with a clinical infection. Only two recipients failed to develop either detectable increase in antibodies or an illness; both had circulating antibodies at the time of intranasal inoculation of ARD secretions. There were three instances in which there was an increase in neutralizing antibodies directed against the RI-67 agent in the absence of a recognizable clinical illness; two of the individuals had antibodies when ARD secretions were inoculated. Those recipients initially inoculated with ARD filtrate who developed antibodies against the RI-67 agent, did not have second attacks of clinical illness when challenged with the ARD filtrate 21 days after the first inoculation. Furthermore, a subsequent rise in antibody titer did not occur. When volunteers were inoculated intranasally with severe common cold (S-CC) filtrate 25 days afterwards, clinical infections occurred in three out of six individuals. They were also susceptible to infection by the primary atypical pneumonia (PAP) filtrate. Conversely, volunteers given S-CC filtrate were not only susceptible to consecutive common cold infections, but subsequently became ill when inoculated with ARD filtrate 25 days after the second S-CC filtrate inoculation. Moreover, these volunteers were also susceptible to infection by the PAP filtrate. The only sera available in this instance to permit demonstration of a rise in antibody to the RI-67 agent were those obtained after the PAP challenge. The group of five volunteers, inoculated successively with autogenous, common cold, and primary atypical pneumonia filtrates, failed to show rises in neutralizing antibody to the RI-67 virus. This result indicates that the rise in specific antibodies in the other groups was not due to the inoculation of primary atypical pneumonia filtrate. Thus the data presented in Figure 1 show that the increase in immune bodies to RI-67 virus resulted from the ARD infection.
The results of neutralization titrations carried out on sera from all recipients inoculated with These data indicate that as a result of inoculation of an ARD filtrate into human volunteers, illness developed in a large proportion (94 per cent) of those who did not have circulating neutralizing antibodies against the RI-67 agent. Furthermore, it may be concluded from these data that the presence in blood of antibodies against this virus is related to an undetermined degree to protection against the causative agent of ARD.
Neutralization titrations with sera from recipients of bronchitis resembling atypical pneumonia and mild common cold filtrates Neutralization titrations carried out with the acute and convalescent phase sera from a patient with a disease syndrome termed "bronchitis resembling atypical pneumonia (Br-AP)" (3) exhibited a marked increase in antibodies against the RI-67 agent (Table I) . Filtered respiratory secretions from this patient were inoculated into human volunteers and pre-and post-inoculation sera from the recipients were subsequently tested. Sera from individuals in the same experiment who were inoculated with secretions from a patient in the acute stage of a mild common cold (CC) were also titrated. The results of these neutralization titrations, as well as the occurrence of illnesses in the inoculated volunteers, are summarized in Figure 2. Only 4 of the 10 volunteers inoculated with Br-AP secretions developed a clinical illness. Sera were available from only three of these individuals, all of whom developed a small increase in neutralizing antibodies. The increase in titer demonstrable, although small, was considered to be significant as the titers were reproducible on repeated neutralization tests. Of the six recipients who showed no indication of infection following intranasal inoculation, four developed an increase in neutralizing antibodies; the rise in two instances was of greater magnitude than noted in sera from recipients with clinical illnesses. None of the recipients who received the common cold filtrate had an increase in neutralizing antibodies against the RI-67 agent. In addition, it will be noted that the recipients given the bronchitis filtrate were not subsequently resistant to the common cold, nor did homologous immunity develop in those who were given common other times a number of types may compete in the production of sporadic cases; or 4) the RI-67 agent occasionally may propagate and stimulate the production of specific antibodies in patients with ARD, although it is not the specific causative agent of the clinical disease observed. The evidence available suggests that the last interpretation is unlikely, but does not permit exclusion of any of -the other possibilities.
Neutralization titrations with pooled gamma globulin and RI-67 agent An estimation of the prevalence of the RI-67 agent in the civilian population could be readily obtained by the determination of the presence of antibodies directed against it in gamma globulin prepared from pooled Red Cross plasma. Seven pools were tested; all contained neutralizing antibodies in titers of 1: 32 (1 pool) or 1:128 (6 pools). Although in low dilutions (1:8 or less) each sample employed had a deleterious effect upon HeLa cells, this did not interfere with the end-point determination which in every instance was at least four-fold higher than the toxic effect of the gamma globulin. One may deduce from these data that the RI-67 agent or one immunologically related to it does propagate in human hosts in the civilian population, and that either infections by this agent occur frequently, or antibodies which develop as a result of infection persist for a relatively long period of time.
Neutralization titrations with A.D. agents (Rowe and co-workers) and sera from donors and recipients in 1945 human transmission experiment Evidence already presented suggests that the RI-67 agent isolated by Hilleman and Werner (6) is etiologically related to the disease entity ARD. From tissues obtained at routine tonsillectomies and adenoidectomies, Rowe and co-workers isolated a number of agents which, in HeLa cell tissue cultures, appeared to have certain characteristics similar to the RI-67 agent (5). It was therefore of interest to compare these agents in neutralization titrations to determine: 1) whether antibodies against the A.D. agents It is proposed however, that it should be possible to obtain sufficient data from detailed clinical and epidemiological studies correlated with laboratory investigation to establish the etiologic relationship of a newly isolated agent with most infectious diseases. The data of importance might be categorized as follows: 1) Isolation of the agent should be possible from the majority of patients with the disease in question; the agent should be obtained from infected tissue or from secretions related to this tissue; 2) Specific antibodies directed against the new agent should develop in relation to infection; and 3) Resistance to infection should be correlated with presence of type specific, neutralizing antibodies; conversely, susceptibility should be related to absence or low titer of these specific antibodies. Perhaps the most definitive evidence in relation to these three points can be obtained when the disease in question occurs in a sequential or epidemic fashion in defined population groups. Data on each of these points have been obtained with the RI-67 agent and ARD and presented by Hilleman and Werner (6) and the present investigation.
Although the epidemic of acute respiratory disease studied by Hilleman and Werner (6) was that of an influenza-like illness considered to be ARD, the RI-67 strain of cytopathogenic agents was isolated from a patient who had a pulmonary infiltration. This infection was diagnosed to be primary atypical pneumonia although a rise in cold hemagglutinins or agglutinins to streptococcus MG did not occur (14) . The data presented (Table I, Figure 1) indicate that in hospitalized patients and human volunteers a number of classical cases of primary atypical pneumonia of the type associated with a rise of cold hemagglutinins was not caused by the RI-67 agent. In addition, a number of hospitalized cases considered clinically to be primary atypical pneumonia in whom no cold hemagglutinins or streptococcus MG agglutinins developed were investigated; none had a rise in titer of neutralizing antibodies against the RI-67 agent. Of 22 cases of ARD which occurred at Sampson Air Force Base in 1953, pulmonary infiltration by x-ray was noted in four cases. Three of these patients manifested an increase in RI-67 neutralizing antibodies. Further laboratory and detailed clinical studies concerning these ill-nesses were not available. These data suggest that pulmonary infiltration may develop during ARD. In the absence of information relative to the etiology-of these infections, these cases would be termed; primary atypical pneumonia. With knowledge of the causal agent, a specific diagnosis can be made. That pulmonary infiltration Unassociated with bacterial infection may develop during the course of an upper respiratory viral disease has been amply demonstrated in influenza infections (15, 16) . (5) . These studies indicated that the acute upper respiratory infection, ARD, was caused by an agent, presumably a virus, identical with or closely related to the RI-67 agent; that the A.D. agents did not produce this illness; and that ARJ) is a clinical entity distinct from the common cold or primary atypical pneumonia. In addition to the RI-67 agent, ARD is probably caused by other-agents, immunologically different from the RI-67 virus. It is proposed that the RI-67 agent be called an ARD virus.
Addendum
Subsequent to the submission of this paper for publication an article entitled "Adenoidal-Pharyngeal-Conjunctiv Agents. A newly Recognized Group of Common Viruses of the Respiratory System," by Huebner,
